Nivelipol

Quick links to important sections

Nivelipol

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Nivelipol

Quick Facts

Classification Bile Acid Sequestrant
Active Ingredient Cholestyramine
Primary Use Hypercholesterolemia (High Cholesterol)

What is Nivelipol?

Nivelipol is a brand name for the medication Cholestyramine, which belongs to a class of drugs called bile acid sequestrants (BASs) or resins. It is prescribed as an adjunct to diet and exercise to help lower elevated levels of Low-Density Lipoprotein (LDL) cholesterol—often referred to as “bad cholesterol”—in patients with primary hypercholesterolemia. Reducing high cholesterol levels is an important part of managing the risk of coronary heart disease and other cardiovascular events.

Mechanism of Action

Nivelipol works primarily in the intestines and is not absorbed into the bloodstream. Its active ingredient, cholestyramine, is an insoluble, non-absorbable resin that binds to bile acids—substances made by the liver from cholesterol. By forming a complex with these bile acids, it prevents them from being reabsorbed from the intestine into the bloodstream, thereby increasing their excretion in the stool.

The body compensates for this loss by converting more cholesterol into new bile acids in the liver. This process requires the liver to pull more LDL cholesterol from the blood, which results in a reduction of total and LDL cholesterol levels in the plasma. Because of its non-systemic action, Nivelipol is considered one of the safer lipid-lowering therapies and may be used alone or in combination with other cholesterol-lowering medications, such as statins.

Regulatory References

  1. NIH StatPearls on Bile Acid Sequestrants
  2. NIH StatPearls on Colestipol

What side effects are possible with Nivelipol?

Possible side effects and safety information

Nivelipol (cholestyramine) is classified as a non-systemic medication, meaning its action is localized to the gastrointestinal (GI) tract. Consequently, the officially documented adverse effects are primarily associated with the digestive system, as detailed in regulatory documents.


Officially Documented Adverse Reactions by System

The most prominent system-organ class affected is Gastrointestinal Disorders. The most frequently reported adverse reaction is constipation, which is often mild and transient. Other common GI effects listed in regulatory summaries include abdominal discomfort, flatulence, nausea, vomiting, diarrhea, and heartburn.

Less frequently, adverse reactions are reported in other systems:

  • Metabolic and Nutritional: Long-term use carries a risk of interfering with the absorption of fat-soluble vitamins (A, D, E, and K), potentially leading to deficiencies such as hyperchloremic acidosis or bleeding tendencies (due to Vitamin K deficiency).
  • Other Systems: Reported effects include rash, skin irritation, and, rarely, osteoporosis or headache.

Serious Adverse Reactions and Safety Constraints

Official labeling documents note intestinal obstruction as a rare but serious adverse event, with reports including fatalities in pediatric patients. Bleeding tendencies resulting from acquired hypoprothrombinemia are also officially documented.

Population-Specific Considerations: Use of Nivelipol is contraindicated in patients with complete biliary obstruction or hypersensitivity to the resin. Specific cautions apply to older adults, who may experience increased constipation risk at higher doses, and pediatric patients, who have an increased risk of hyperchloremic acidosis. Certain sugar-free formulations are contraindicated for individuals with Phenylketonuria (PKU).

Overdose and Emergency Response

Overdose: When to Seek Immediate Medical Help

Nivelipol overdose, or the suspected ingestion of an excessively large dose, is a medical emergency that requires prompt professional attention. While Nivelipol is not systemically absorbed, an acute overdose is primarily associated with pronounced effects within the gastrointestinal system.

Documented Overdose Symptoms

Regulatory information indicates that the most common clinical manifestations of an overdose are related to the drug's mechanism of action in the intestines, which may include:

  • Severe Constipation: A significant, persistent, or impactful blockage of the bowels.
  • Gastrointestinal Obstruction: In severe cases, high-dose exposure or exposure in certain individuals may lead to a bowel obstruction.
  • Abdominal Distress: Severe or cramping stomach pain, potentially accompanied by significant nausea or vomiting.

Required Emergency Action

It is critical to contact emergency medical services or a poison control center immediately if an overdose of Nivelipol is suspected. In cases of severe clinical presentation, such as profound abdominal pain or signs of potential obstruction, immediate transport to an emergency department is necessary.

Medical management will focus on supportive care and monitoring of gastrointestinal function. The non-absorbable nature of Nivelipol means systemic toxicity is not the primary risk; rather, the focus is on mitigating local mechanical effects in the digestive tract. Always bring the product container and any relevant information to the medical professionals.

Therapeutic Uses of Nivelipol

What Nivelipol Treats: Main Uses and Benefits

Nivelipol is commonly used to help manage distinct clinical needs primarily across metabolic and gastrointestinal therapeutic domains. This medication is applied in situations involving elevated serum cholesterol, pruritus, and specific forms of chronic diarrhea.

Therapeutic Scope

Nivelipol is generally applied as adjunctive therapy to diet for the reduction of significantly elevated levels of LDL cholesterol in patients with primary hypercholesterolemia, a key risk factor for cardiovascular disease. It is also relevant for easing severe, persistent generalized itching (pruritus) associated with chronic cholestatic diseases and for controlling chronic, persistent watery diarrhea stemming from bile acid excess.

This application may assist with supporting functional stability and contributes to easing the overall symptom load.

Quick Fact: Symptom Domains
Metabolic: Lowering elevated LDL cholesterol
Gastrointestinal: Controlling bile-acid induced diarrhea
Dermatological: Easing severe cholestatic pruritus

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Nivelipol? (Official Eligibility)

Nivelipol (Fenofibrate) is a prescription medicine intended strictly for use by adults. Eligibility is determined by excluding groups with specific underlying health conditions or life stages, as defined in official regulatory documents.

Contraindications (Who Must Not Use Nivelipol)

Regulatory agencies strictly contraindicate the use of Nivelipol in patients with the following conditions or states:

Exclusion Category Regulatory Status
Severe Renal Impairment (including dialysis) Contraindicated
Active Liver Disease (including primary biliary cirrhosis) Contraindicated
Pre-existing Gallbladder Disease Contraindicated
Known Hypersensitivity to fenofibrate or its components Contraindicated
Lactation (Nursing Mothers) Contraindicated

Restricted and Ineligible Populations

Nivelipol is not recommended or has eligibility limitations for the following groups:

Population Group Eligibility Status
Pediatric Patients (children and adolescents) Safety and Efficacy Not Established
Mild to Moderate Renal Impairment Use Permitted, requires Dose Reduction and monitoring
Pregnancy Use Only if Potential Benefit Justifies Risk

Use in geriatric patients also requires careful consideration based on their renal function.

What should I know about interactions with other medicines?

The official regulatory profile for Nivelipol (Cholestyramine) is primarily characterized by a non-systemic reduced systemic exposure pharmacokinetic interaction. This occurs because the medication binds to co-administered oral drugs and substances within the gastrointestinal tract, leading to their reduced absorption and potentially lower systemic levels.

Category Official Regulatory Documentation Statement
Interacting Medicines Thyroid hormones (e.g., Levothyroxine), Coumarin anticoagulants (e.g., Warfarin), Cardiac glycosides (e.g., Digoxin), Thiazide diuretics, and certain antibiotics (e.g., Penicillin G) .
Nutrient/Supplement Interaction Reduced absorption of fat-soluble vitamins (A, D, E, K) and Folic Acid is documented, particularly with prolonged use .
Pharmacodynamic Interaction An additive lipid-lowering effect is noted when Nivelipol is combined with other lipid-modifying agents, such as HMG-CoA reductase inhibitors (statins) .

To mitigate the absorption-reducing interaction, regulatory labels establish a mandatory timing rule: most orally administered medications must be taken at least one hour before Nivelipol or four to six hours after Nivelipol . No metabolic (CYP-mediated) or transporter-mediated interactions are documented, as Nivelipol is not absorbed into the bloodstream. A potential population-specific consideration for those with certain underlying conditions is the risk of hyperchloremic acidosis . The overall interaction structure is centered on strict administration separation to preserve the intended therapeutic effect of co-administered agents.

: Based on FDA Prescribing Information and SmPC documents. : Based on FDA and MHRA regulatory information. : Based on NIH and regulatory cautions.

Mechanism of Action

Disruption of Enterohepatic Circulation

Nivelipol works by sequestration, where the insoluble resin, cholestyramine, chemically binds to bile acids in the small intestine. This action prevents their normal reabsorption via the enterohepatic circulation, causing their increased excretion from the body. This mechanism is entirely non-systemic and initiates the resulting physiological cascade.

Compensatory Hepatic Cholesterol Clearance

The liver compensates for the loss of bile acids by increasing their synthesis rate, which requires increased cholesterol as a precursor. To meet this metabolic demand, the liver dramatically upregulates the expression of Low-Density Lipoprotein (LDL) receptors on its surface. This compensatory mechanism enhances the rate of LDL clearance from the blood plasma; the resulting physiological change is a net decrease in circulating LDL-C.

Dosage and Administration Information

How to Use Nivelipol (Simvastatin)

The instructions for the use of this medicine, which contains the active ingredient simvastatin, define a standardized administration procedure. These instructions are provided to ensure consistent and correct use of the medication.

Administration scope

Instruction Category Statement
Route of administration Oral (by mouth)
Dosing schedule Typically taken once daily in the evening
Timing in relation to meals Can be taken with or without food
Preparation requirements None; the tablet must be swallowed whole
Age-group administration rules Dosing may differ for adolescents and children, depending on body size and medical condition.
Missed-dose rules If a dose is missed, take it as soon as you remember unless it is almost time for your next scheduled dose. If so, skip the missed dose and continue the regular schedule. Do not take two doses at the same time to make up for a missed one.
Special procedural conditions The maximum initial dose is often defined for patients receiving certain concomitant therapies. The dose must be taken in the evening to optimize its effect.

Instruction classifications (high-level)

Classification Detail
Administration method type Oral
Frequency pattern Once daily
Basis Governed by established standards for medication use.
Use-context constraints Must be used in conjunction with a diet and exercise program.

Resulting procedural structure Official step sequence:

  • Swallow the tablet whole, without crushing or chewing.
  • Take the prescribed dose once daily.
  • Time administration to occur in the evening.

Connection to the overall use protocol: These instructions define the route (oral) and frequency (once daily, evening) of administration. The procedural structure ensures the medicine is consistently introduced into the body at the specified time, without requiring specialized preparation steps.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Nivelipol


1. Evidence for Use in Primary Hypercholesterolemia

Nivelipol (cholestyramine) was evaluated in research exploring how systemic factors change in populations characterized by primary hypercholesterolemia. The evidence base includes large-scale, long-term Randomized Controlled Trials (RCTs), as well as secondary prevention trials exploring outcomes in patients with pre-existing heart disease.

Researchers examined outcomes related to systemic or functional imbalance, specifically monitoring changes in blood cholesterol levels. Studies also tracked key clinical endpoints, such as the frequency of cardiovascular events over defined time intervals. Studies reported patterns observed in these trials, describing the measured change in LDL cholesterol levels in the observed groups. Research also explored changes measured during the study period related to the frequency of cardiovascular events in the observed populations.


2. Evidence for Use in Cholestatic Pruritus

Research has explored Nivelipol's use in studies examining patient-reported experiences of severe generalized itching, or pruritus, in populations characterized by cholestatic diseases (conditions affecting bile flow). The available evidence includes small-scale clinical trials and observational case reports. These trials were relevant in trials assessing short-term or episodic symptom patterns, primarily by measuring outcomes related to physical discomfort.

Studies monitored how symptoms evolved in the observed populations using patient-reported outcome scales to measure the intensity of itching. Research provides insight into short-term changes and describes the measured changes in reported itching severity. Findings describe patterns observed in the studies where symptom changes were observed in some studies within the first few weeks of administration. Studies report that the measured changes in bile acid levels in the blood were not always found to align consistently with the patient-reported outcomes describing perceived discomfort.


3. Evidence in Special Populations and Limitations

Research has explored the use of Nivelipol in children and adolescents (typically those aged 10–17) who were associated with inherited forms of high cholesterol. These studies monitored changes in LDL cholesterol levels in this younger population. However, data for certain groups remain insufficient. For instance, there is limited information for long-term outcomes specifically for the pediatric population, and follow-up durations were limited in some of these groups. Subgroup findings are uncertain regarding the full range of outcomes for older adults or individuals presenting with specific, complex co-morbidities.

Evidence quality varies across studies. Challenges with patient adherence were noted in many trials, which contributes to the research limitation frames regarding long-term patterns outside of supervised study environments. There is limited information for long-term outcomes related to chronic bile acid diarrhea or sustained symptom relief in pruritus.

Key Studies & References

  1. Cholestyramine: MedlinePlus Drug Information
  2. Cholestyramine: MedlinePlus Drug Information (Alternative/Pruritus Use)
  3. Colestipol: StatPearls - NCBI Bookshelf (Context for BAS Class)

Frequently Asked Questions (FAQ)

Common questions about Nivelipol (FAQ)


Q: Why is Nivelipol prescribed instead of other similar drugs?

A: Regulatory guidelines describe Nivelipol as a medication used alongside diet and exercise. It is often considered when patients do not reach their cholesterol goals with other initial therapies, or when agents like statins are not tolerated. Its distinct mechanism of action means it is sometimes described as an adjunctive (add-on) treatment.


Q: What is the difference between Nivelipol and drug X (a common competitor)?

A: Nivelipol belongs to the drug class known as bile acid sequestrants, which work locally by binding substances in the intestine. This mechanism of action is distinctly different from a class of drugs like statins, which are absorbed into the bloodstream and work primarily in the liver. Official sources note that newer drugs in this class are described as having different characteristics regarding gastrointestinal tolerability.


Q: How quickly does Nivelipol usually start working?

A: Clinical studies indicate that the majority of the low-density lipoprotein (LDL) cholesterol reduction is generally observed within the first two to four weeks after starting therapy. This timeframe for the onset of effect is derived from regulatory summaries of clinical efficacy data.


Q: Does Nivelipol have to be taken indefinitely?

A: Official patient information indicates that Nivelipol is prescribed to help control a chronic condition, such as high cholesterol, rather than cure it. Therefore, continued administration is typically prescribed long-term to help sustain the intended therapeutic effect, as defined in official information.


Q: How long does Nivelipol stay in your system?

A: Nivelipol is unique because it is a non-systemic medication, meaning it is not absorbed from the digestive tract into the bloodstream. After it binds to bile acids in the gut, the resulting complex is entirely eliminated in the feces, meaning it does not have a measurable half-life in the bloodstream.


Q: What is the official recommended use period for Nivelipol?

A: Regulatory information describes the use period as generally ongoing because the medication is intended to help manage a chronic condition and requires continued administration to maintain the intended effect.


Q: Are there any known interactions between Nivelipol and alcohol?

A: Official patient information notes that the use of alcohol may potentially interact with Nivelipol. Individuals are generally directed to consult their healthcare provider regarding its use.


Q: Has Nivelipol received a Black Box Warning from the FDA?

A: The FDA has not issued a Black Box Warning for Nivelipol (Cholestyramine). The prescribing information does, however, document serious adverse reactions, including intestinal obstruction and bleeding tendencies.


Q: Does Nivelipol interact with birth control pills?

A: Official labeling notes that Nivelipol may interfere with the absorption of estrogens and progestins, which are active components in some birth control pills. To manage this potential interaction, regulatory documents describe a specific separation time between taking Nivelipol and the birth control medication.


Q: Can Nivelipol be crushed, chewed, or split?

A: The product is provided as a powder that must always be thoroughly mixed with liquid or a soft food before being taken. Official administration instructions emphasize that the dry powder should never be swallowed alone. This is due to an officially documented safety caution regarding the risk of it causing a blockage in the throat (esophageal obstruction).


Q: What is the general success rate mentioned in clinical trials for Nivelipol?

A: Clinical studies have examined the potential effect of Nivelipol (cholestyramine) on cholesterol levels. These trials report an average reduction of LDL cholesterol of approximately 18% to 25% in the study population when the medicine was used at standard doses. This figure represents an observed pattern in a study group.


Q: Does Nivelipol interact with common vitamins like Vitamin D?

A: Official patient information states that Nivelipol may interfere with the body's absorption of fat-soluble vitamins (Vitamins A, D, E, and K). This includes Vitamin D. This interaction is attributed to the medication's mechanism of action, which involves the non-systemic binding of substances in the gut.


Q: Does Nivelipol change how my thyroid medication works?

A: Regulatory documents state that Nivelipol may interfere with the absorption of thyroid hormone replacement medicines (such as Levothyroxine). Regulatory information indicates a necessary separation of administration by a specific time interval to help manage this interaction and maintain the thyroid medicine's intended effect.

How should Nivelipol be stored and disposed of?

Storage and Disposal Requirements

Nivelipol (Cholestyramine) must be stored and disposed of according to strict regulatory guidelines to maintain its stability and ensure safety.


Storage Conditions

  • Temperature: Store the dry powder at Controlled Room Temperature, typically 20 C to 25 C. The product must be kept from freezing and should not be stored above 30 C.
  • Protection: Keep the medication in the original container, tightly closed, and protect it from excess heat, moisture, and direct light.
  • Prepared Dose Stability: The suspension, once mixed with liquid, can be stored refrigerated for up to 3 days.

Disposal and Safety

  • Child Safety: It is mandatory to keep the product out of the sight and reach of children.
  • Disposal: Unused or expired medicine must be disposed of in accordance with local regulations. The drug is not to be flushed down drains. Preferred disposal involves using a drug take-back program or mixing the powder with an undesirable substance before discarding it in the household trash.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Nivelipol found in:

A-Z Index: